Medical Properties Trust Q3 2026 earnings

MPT · 2026-10-29 08:18 BMO ET · 8-K on SEC · 10-Q on SEC

Net income swung to a $202 million profit in Q3, supported by $680 million in asset sale proceeds and a $157.8 million gain on sale of real estate, though normalized FFO declined to $63.8 million.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$250.1M+5.3%-3.5%Ex. 99.1, income statement
EPS (GAAP)$0.34+362%+3500%Ex. 99.1, income statement
Net income$202.0M+360%+8800%Ex. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin N/A
  • Operating expenses $263.9M (+7.0% YoY)
  • One-offs in the quarter Gain on sale of real estate $157.8M; Debt refinancing and unutilized financing benefit $69.5M; Real estate impairment charges $23.9M; Litigation, bankruptcy and other costs $2.4M
  • Effective tax rate 4.7% (prior-year 16.3%, year-to-date 5.8%)
  • Non-GAAP bridge Adds back depreciation and amortization ($85.5M), impairment charges ($12.1M), and other non-cash items (share-based comp, non-cash fair value adjustments, tax rate changes, debt costs) to arrive at Normalized FFO ($63.8M).

KPIs

MetricActualPrior quarterPrior yearChange
Normalized FFO$63.8M$92.0M$77.2M-30%
Asset sale proceeds$680M$0$0N/A
Portfolio cash rents (2027)$1.0B+$1.0B+$1.0B+N/A

Guidance

not stated in the 8-K

What drove it

  • Revenue story Total revenue decreased 3.5% QoQ to $250.1M, driven by a 2.9% QoQ decline in rent billed to $195.3M, offset by a 3.2% QoQ increase in straight-line rent.
  • EPS story The $0.34 EPS was driven by a $157.8M gain on sale of real estate and a $69.5M debt refinancing benefit, while NFFO was negatively impacted by a $2.4M reduction due to HSA's revenue collection challenges.
  • One-off check Gain on sale of real estate $157.8M (non-recurring), Debt refinancing and unutilized financing benefit $69.5M (non-recurring), Real estate impairment charges $23.9M (non-recurring), Litigation, bankruptcy and other costs $2.4M (non-recurring).

The good

  • Net income turned positive to $202M
  • $680M in asset sale proceeds available for debt repayment

The bad

  • Normalized FFO declined 30% QoQ to $63.8M
  • HSA revenue collection challenges reduced NFFO by $2.4M

The ugly

  • none

Open questions

  • The release does not disclose the specific amount of the $680 million asset sale proceeds that were used for debt repayment.
  • The release does not disclose the specific amount of the $2.4 billion private refinancing transaction announced in Q2.
Full release

Medical Properties Trust (MPT) earnings release, October 29, 2026

Medical Properties Trust Inc (MPT) · Form 8-K, Item 2.02 · Filed · SEC filing

Contact: Charles Lambert

Senior Vice President of Finance & Treasurer

Medical

Properties Trust, Inc.

(205)

397-8897 clambert@mpt.com

MPT REPORTS THIRD

QUARTER RESULTS

Completed Previously Announced Transactions that Provided Approximately $680 Million in Asset Sale Proceeds and

Significantly Extended Debt Maturities

Birmingham, AL – October 29, 2026 – Medical Properties Trust, Inc. (the

“Company” or “MPT”) (NYSE: MPT) today announced financial and operating results for the third quarter ended September 30, 2026, as well as certain events occurring subsequent to quarter end.

Edward K. Aldag, Jr., Chairman, President and Chief Executive Officer, said, “Our results this quarter demonstrate the decisive steps we have taken to strengthen our balance sheet and create greater flexibility to further reduce debt and pursue selective growth opportunities. As healthcare providers around the world seek new solutions to capital challenges, our business model is more important than ever and we are well positioned to create long-term value for our shareholders.

“We are closely monitoring operations at HSA as they navigate continued revenue cycle management challenges that precluded payment of September rent, reducing our NFFO by two cents during the quarter. HSA recently engaged a leading management services provider, Ovation Healthcare, to oversee operations across the portfolio and improve billings and collections.”

Included in the financial tables accompanying this press release is information about the

Company’s assets and liabilities, operating results, and reconciliations of net income (loss) to NFFO, including per share amounts, all on a basis comparable to 2025 results.

PORTFOLIO UPDATE

MPT has total assets of approximately $14.4 billion, including $8.3 billion of general acute facilities, $2.4 billion of behavioral health facilities and $1.6 billion of post-acute facilities. As of September 30, 2026, MPT’s portfolio included 365 properties and approximately 37,000 licensed beds leased to or mortgaged by 52 hospital operating companies across the United States, as well as in the United Kingdom, Switzerland, Germany, Spain, Finland, Colombia, Italy and Portugal.

As previously disclosed, during the quarter, the Company sold its remaining interest in five hospitals in

Utah for approximately $174 million. Additionally, the Company sold its interest in the real estate of two hospitals in Idaho to affiliates of Intermountain Health, an investment grade not-for-profit healthcare system, for approximately $371 million. The sales prices for each of these transactions significantly exceeded the Company’s original investments, again demonstrating the overall value of its portfolio of hospital real estate. Moreover, these and other recent transactions have provided $680 million in proceeds that are available for repayment of debt and other balance sheet improvement.

The Company continues to expect portfolio cash rents in excess of $1.0 billion in 2027, even after reduction of the rental income associated with assets sold in the third quarter. In addition, this estimate includes conservative assumptions about rental income associated with cash basis tenants, including HSA, which continues to be challenged by revenue collection and for whom the Company has recently provided additional working capital support during the quarter.

OPERATING RESULTS

Net income for the third quarter ended September 30, 2026 was $202 million ($0.34 per share), compared to a net loss of ($78 million) (($0.13) per share) in the year earlier period. NFFO for the third quarter ended September 30, 2026 was $64 million ($0.11 per share), compared to $77 million ($0.13 per share) in the year earlier period.

CONFERENCE CALL AND WEBCAST

The Company has scheduled a conference call and webcast for October 29, 2026, at 11:00 a.m. Eastern Time to present the Company’s financial and operating results for the quarter ended September 30, 2026. The dial-in numbers for the conference call are

833-461-5787

(Toll-Free) and

585-542-9983, and the Meeting ID is 336661409 to join the conference. The conference call and webcast replay will also be available via webcast in the Investor Relations section of the Company’s website, www.mpt.com. The webcast replay will be available for one year.

The Company’s supplemental information package for the current period will also be available on the Company’s website in the Investor Relations section.

The Company uses, and intends to continue to use, the Investor

Relations page of its website, which can be found at www.mpt.com, as a means of disclosing material nonpublic information and complying with its disclosure obligations under Regulation FD, including, without limitation, through the posting of investor presentations that may include material nonpublic information. Accordingly, investors should monitor the Investor Relations page, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.

About Medical Properties Trust, Inc.

Medical Properties

Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities. From its inception in Birmingham, Alabama, the Company has grown to become one of the world’s largest owners of hospital real estate with 365 facilities and approximately 37,000 licensed beds in nine countries and across three continents as of September 30, 2026. MPT’s financing model facilitates acquisitions... (truncated) please visit the Company’s website at www.mpt.com.

Financial statements

Income Statement

For the Three Months Ended — (Unaudited) (Amounts in thousands, except for per share data)

For the Three Months Ended – September 30, 2026For the Three Months Ended – September 30, 2025For the Nine Months Ended – September 30, 2026For the Nine Months Ended – September 30, 2025
Revenues
Rent billed195,305181,001596,225524,051
Straight-line rent35,69936,405103,203116,197
Income from financing leases10,0999,94430,24429,772
Interest and other income9,03710,17231,81631,660
Total revenues250,140237,522761,488701,680
Expenses
Interest153,091132,395421,683377,905
Real estate depreciation and amortization70,34366,993209,513198,282
Property-related (A)11,3998,99332,54126,891
General and administrative29,03637,73496,012105,842
Total expenses263,869246,115759,749708,920
Other income (expense)
Gain (loss) on sale of real estate157,766-9,115163,4384,156
Real estate and other impairment charges, net-23,870-81,761-59,670-159,284
Earnings from equity interests6,98834,40334,13573,713
Debt refinancing and unutilized financing benefit (costs)69,524-1469,524-3,629
Other (including fair value adjustments on securities)15,424-1,49811,011-171,138
Total other income (expense)225,832-57,985218,438-256,182
Income (loss) before income tax212,103-66,578220,177-263,422
Income tax (expense) benefit-10,026-10,87212,719-30,112
Net income (loss)202,077-77,450232,896-293,534
Net income attributable to non-controlling interests-494-280-1,081-828
Net income (loss) attributable to MPT common stockholders201,583-77,730231,815-294,362
Earnings per common share - basic and diluted:
Net income (loss) attributable to MPT common stockholders0.34-0.130.39-0.49
Weighted average shares outstanding - basic597,157601,136597,611600,867
Weighted average shares outstanding - diluted597,162601,136597,613600,867
Dividends declared per common share0.090.080.270.24

Income Statement

For the Three Months Ended — (Unaudited) (Amounts in thousands, except for per share data)

For the Three Months Ended – September 30, 2026For the Three Months Ended – September 30, 2025For the Nine Months Ended – September 30, 2026For the Nine Months Ended – September 30, 2025
FFO information:
Net income (loss) attributable to MPT common stockholders201,583-77,730231,815-294,362
Participating securities’ share in earnings-353-256-1,221-597
Net income (loss), less participating securities’ share in earnings201,230-77,986230,594-294,959
Depreciation and amortization85,53082,242257,433240,465
(Gain) loss on sale of real estate-155,4529,115-159,990-4,156
Real estate impairment charges12,12378,67722,765126,645
Funds from operations143,43192,048350,80267,995
Other impairment charges, net13,7566,97639,54940,487
Litigation, bankruptcy and other costs2,413-1,1255,48011,078
Share-based compensation (fair value adjustments) (A)-8,0753,457-21,3623,444
Non-cash fair value adjustments-18,206-12,066-21,539123,370
Tax rate changes and other21-12,091-45,134-10,970
Debt refinancing and unutilized financing (benefit) costs-69,52414-69,5244,273
Normalized funds from operations63,81677,213238,272239,677
Certain non-cash and related recovery information:
Share-based compensation (A)8,4578,88527,17827,420
Debt costs amortization4,8147,44519,48020,435
Non-cash rent and interest revenue (B)4693491,096349
Cash recoveries of non-cash rent and interest revenue (C)$—5562101,620
Straight-line rent revenue from operating and finance leases-39,252-39,688-110,979-124,945
Per diluted share data:
Net income (loss), less participating securities’ share in earnings0.34-0.130.39-0.49
Depreciation and amortization0.140.140.430.4
(Gain) loss on sale of real estate-0.260.01-0.27-0.01
Real estate impairment charges0.020.130.030.21
Funds from operations0.240.150.580.11
Other impairment charges, net0.020.010.070.06
Litigation, bankruptcy and other costs0.010.010.02
Share-based compensation (fair value adjustments) (A)-0.010.01-0.030.01
Non-cash fair value adjustments-0.03-0.02-0.040.21
Tax rate changes and other-0.02-0.07-0.02
Debt refinancing and unutilized financing (benefit) costs-0.12-0.120.01

Balance Sheet

September 30, 2026 — Consolidated Balance Sheets (Amounts in thousands, except for per share data)

September 30, 2026 – (Unaudited)December 31, 2025 – (A)
Real estate assets
Land, buildings and improvements, intangible lease assets, and other11,921,01512,205,687
Investment in financing leases384,419421,684
Mortgage loans131,726123,651
Gross investment in real estate assets12,437,16012,751,022
Accumulated depreciation and amortization-1,768,594-1,663,056
Net investment in real estate assets10,668,56611,087,966
Cash and cash equivalents599,282540,859
Interest and rent receivables19,13719,210
Straight-line rent receivables944,326881,452
Investments in unconsolidated real estate joint ventures1,045,4751,399,777
Investments in unconsolidated operating entities320,740322,179
Other loans283,015186,292
Other assets513,155564,040
Total Assets14,393,69615,001,775
Liabilities
Debt, net9,260,2579,697,835
Accounts payable and accrued expenses398,703549,105
Deferred revenue16,93019,289
Obligations to tenants and other lease liabilities95,380128,297
Total Liabilities9,771,27010,394,526
Equity
Common stock, $0.001 par value. Authorized 750,000 shares; issued and outstanding - 597,157 shares at September 30, 2026 and 597,008 shares at December 31, 2025597597
Additional paid-in capital8,583,1018,573,396
Retained deficit-4,066,730-4,136,011
Accumulated other comprehensive income104,405168,213
Total Medical Properties Trust, Inc. stockholders’ equity4,621,3734,606,195
Non-controlling interests1,0531,054
Total Equity4,622,4264,607,249
Total Liabilities and Equity14,393,69615,001,775

Cash Flow

From the 10-Q · For the Nine Months Ended September 30, — (Unaudited) (in thousands)

For the Nine Months Ended September 30, – 2026For the Nine Months Ended September 30, – 2025
Operating activities
Net income (loss)232,896-293,534
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization221,460203,145
Amortization of deferred financing costs and debt discount17,82119,364
Straight-line rent revenue from operating and finance leases-108,322-120,674
Stock-based compensation5,81530,864
Gain on sale of real estate-163,438-4,156
Real estate and other impairment charges, net62,314167,132
Debt refinancing and unutilized financing (benefit) costs-69,5243,629
Earnings from equity and other interests-34,135-73,713
Distributions of earnings from equity and other interests84,88030,502
Tax rate changes and other-43,546997
Non-cash fair value adjustments-10,526157,592
Other adjustments-9,312-11,437
Changes in:
Interest and rent receivables318,305
Other assets-9315,491
Accounts payable and accrued expenses-94,383-45,719
Deferred revenue-1,773-7,085
Net cash provided by operating activities89,32770,703
Investing activities
Cash paid for acquisitions and other related investments-29,322-110,089
Net proceeds from sale of real estate389,90096,961
Proceeds received from repayment of loans receivable126,70510,049
Investment in loans receivable-186,452-158,974
Construction in progress and other-25,592-60,747
Sale and return of equity investment222,042
Capital additions and other investments, net-60,227-34,069
Net cash provided by (used for) investing activities437,054-256,869
Financing activities
Proceeds from term debt962,6872,512,970
Payments of term debt-968,837-2,252,731
Revolving credit facility, net-249,574171,530
Dividends paid-163,788-144,840
Lease deposits and other obligations to tenants1,5742,475
Offering costs-262-644
Stock vesting - satisfaction of tax withholdings-3,739-1,478
Repurchase of common stock-6,123
Payment of debt refinancing and deferred financing costs and other financing activities-44,359-50,218
Net cash (used for) provided by financing activities-472,421237,064
Increase in cash, cash equivalents, and restricted cash for period53,96050,898
Effect of exchange rate changes4,17613,562
Cash, cash equivalents, and restricted cash at beginning of period543,995335,173
Cash, cash equivalents, and restricted cash at end of period602,131399,633
Interest paid471,927393,100
Supplemental schedule of non-cash investing activities:
Real estate and other assets provided in property exchange158,706$—
Real estate acquired in property exchange165,500
Supplemental schedule of non-cash financing activities:
Term debt issued in note exchange1,437,313$—
Term debt retired in note exchange1,560,307
Dividends declared, unpaid54,09748,419
Beginning of period:
Cash and cash equivalents540,859332,335
Restricted cash, included in Other assets3,1362,838
543,995335,173
End of period:
Cash and cash equivalents599,282396,577
Restricted cash, included in Other assets2,8493,056
602,131399,633

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “would”, “could”,

“expect”, “intend”, “plan”, “estimate”, “target”, “anticipate”, “believe”, “objectives”, “outlook”, “guidance” or other similar words, and include statements regarding our strategies, objectives, prospects, asset sales and the expected proceeds and gains therefrom, refinancings (including the timing of, and expected proceeds from, such refinancings), tenant arrangements

(including master leases and lease restructurings, and the expected timing, anticipated rent and financial impact thereof), among others. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results or future events to differ materially from those expressed in or underlying such forward-looking statements, including, but not limited to: (i) the risk that projected rents may be lower than anticipated or realized later than expected;

(ii) the risk that the timing, outcome and terms of the causes of action of Prospect Medical Holdings, Inc. (“Prospect”), which serve as collateral for debtor-in-possession and other fundings provided by MPT that remain outstanding, and of other recoveries in respect of the Company’s remaining Prospect investment, will not be consistent with those anticipated by the Company; (iii) our success in implementing our business strategy and our ability to identify, underwrite, finance, consummate and integrate acquisitions and investments; (iv) the risk that previously announced or contemplated property sales, loan repayments, and other capital recycling transactions do not occur as anticipated or at all; (v) the risk that MPT is not able to attain its leverage, liquidity and cost of capital objectives within a reasonable time period or at all; (vi) MPT’s ability to obtain or modify the terms of debt financing on attractive terms or at all, as a result of changes in interest rates and other factors, which may adversely impact our ability to pay down, refinance, restructure or extend our indebtedness, including extending our 2026 credit facility, as it becomes due, or pursue acquisition and development opportunities; (vii) the ability of our tenants, operators and borrowers to satisfy their obligations under their respective contractual arrangements with us; (viii) the ability of our tenants and operators to operate profitably and generate positive cash flow, remain solvent, comply with applicable laws, rules and regulations in the operation of our properties, to deliver high-quality services, to attract and retain qualified personnel and to attract patients; (ix) the risk that we are unable to monetize our investments in certain tenants at full value within a reasonable time period or at all; (x) the risk that the operations of our tenants will be negatively impacted by changes to Medicaid funding introduced by the OBBBA; (xi) the risks and uncertainties of litigation or other regulatory proceedings; and (xii) the impact of any governmental actions affecting our properties.

The risks described above are not exhaustive and additional factors could adversely affect our business and financial performance, including the risk factors discussed under the section captioned “Risk Factors” in our most recent Annual Report on Form

10-K and our Quarterly Reports on Form

10-Q, and as may be updated in our other filings with the SEC. Forward-looking statements are inherently uncertain and actual performance or outcomes may vary materially from any forward-looking statements and the assumptions on which those statements are based. Readers are cautioned not to place undue reliance on forward-looking statements as predictions of future events.

We disclaim any responsibility to update such forward-looking statements, which speak only as of the date on which they were made.

# #

#

MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES

Consolidated Statements of Income

(Unaudited)

MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES

Reconciliation of Net Income (Loss) to Funds From Operations

(Unaudited)

Notes:

Investors and analysts following the real estate industry utilize funds from operations (“FFO”) as a supplemental performance measure. FFO, reflecting the assumption that real estate asset values rise or fall with market conditions, principally adjusts for the effects of GAAP depreciation and amortization of real estate assets, which assumes that the value of real estate diminishes predictably over time. We compute FFO in accordance with the definition provided by the National Association of Real Estate

Investment Trusts, or Nareit, which represents net income (loss) (computed in accordance with GAAP), excluding gains (losses) on sales of real estate and impairment charges on real estate assets, plus real estate depreciation and amortization, including amortization related to in-place lease intangibles, and after adjustments for unconsolidated partnerships and joint ventures.

In addition to presenting FFO in accordance with the Nareit definition, we disclose normalized FFO, which adjusts FFO for items that relate to unanticipated or non-core events or activities or accounting changes that, if not noted, would make comparison to prior period results and market expectations less meaningful to investors and analysts. We believe that the... (truncated) makes comparisons of our operating results with prior periods and other companies more meaningful. While FFO and normalized FFO are relevant and widely used supplemental measures of operating and financial performance of REITs, they should not be viewed as a substitute measure of our operating performance since the measures do not reflect either depreciation and amortization costs or the level of capital expenditures and leasing costs (if any not paid by our tenants) to maintain the operating performance of our properties, which can be significant economic costs that could materially impact our results of operations. FFO and normalized FFO should not be considered an alternative to net income (loss) (computed in accordance with GAAP) as indicators of our results of operations or to cash flow from operating activities

(computed in accordance with GAAP) as an indicator of our liquidity.

Certain line items above (such as depreciation and amortization) include our share of such income/expense from unconsolidated joint ventures. These amounts are included with all activity of our equity interests in the “Earnings from equity interests” line on the consolidated statements of income.

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.